Arvinas, a biotech company specializing in targeted protein degradation therapies, will announce its first quarter 2026 financial results on May 12, 2026. The company will provide a corporate update via a live webcast accessible on its investor website. Arvinas recently gained FDA approval for VEPPANU, the first PROTAC drug for advanced breast cancer, and is advancing several other drug candidates in clinical trials. This update will offer insights into their financial health and progress in drug development.
C-Lingo, a Hong Kong-based company, introduced a new AI-driven platform on May 23, 2026, to transform Chinese language education in Vietnam. The platform uses a unique "Connected Learning" model combining AI personalization and gamification to enhanc...
The Pentagon has informed Japan that delivery of 400 Tomahawk cruise missiles, ordered in 2024 under a $2.35 billion deal, will face delays of up to two years. This is due to the US military prioritizing replenishment of missile stockpiles heavily us...
Uber Technologies Inc. has made a full takeover offer for Delivery Hero at €33 per share, slightly below Delivery Hero's recent closing price. Prior to the offer, Uber increased its stake in Delivery Hero from about 7% to 19.5%, becoming the largest ...
Clearpool has originated $930 million in institutional credit loans since its 2021 launch, focusing on bringing real-world borrowing onto blockchain with a compliance-first approach. The protocol targets institutional borrowers like hedge funds and f...
StablR's euro (EURR) and dollar (USDR) stablecoins lost their pegs following a security breach where an attacker compromised a private key controlling minting permissions. The attacker minted 12.85 million tokens and converted them through decentrali...
